DASH vs DNLI · P/E 76, rev $13.72B vs $2.11B cap
DoorDash, Inc. Class A Common Stock (DASH) versus Denali Therapeutics Inc (DNLI) — a side-by-side from cached financials, not a winner call.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Denali Therapeutics Inc (DNLI) is a biotechnology company listed on US.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Latest reported DNLI revenue for 2024-12-31 was $0. Net income was -$422.8M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. DNLI currently screens at market cap $2.11B.
DASH currently screens at market cap $69.41B and trailing P/E 75.9. DNLI currently screens at market cap $2.11B.
Not investment advice. Open the DASH and DNLI stock pages for the full models.
Not investment advice.